Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 2
2005 4
2006 4
2007 7
2008 8
2009 7
2010 7
2011 8
2012 9
2013 13
2014 10
2015 14
2016 15
2017 9
2018 8
2019 3
2020 5
2021 5
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L, Heskamp S, Desar IME, Menke-van der Houven van Oordt CW, van der Veldt AAM, Arens AIJ, Brouwers AH, Eisses B, Mulders PFA, Hoekstra OS, Zwezerijnen GJC, van der Graaf WTA, Aarntzen EHJG, Oyen WJG, van Herpen CML. Verhoeff SR, et al. Among authors: mulders pfa. Clin Cancer Res. 2023 Feb 1;29(3):592-601. doi: 10.1158/1078-0432.CCR-22-0921. Clin Cancer Res. 2023. PMID: 36394882 Free PMC article.
Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer.
Oosterwijk-Wakka JC, de Weijert MCA, Franssen GM, Kolev DR, de Haan TAFJ, Boerman OC, Mulders PFA, Oosterwijk E. Oosterwijk-Wakka JC, et al. Among authors: mulders pfa. Neoplasia. 2022 Oct;32:100826. doi: 10.1016/j.neo.2022.100826. Epub 2022 Jul 22. Neoplasia. 2022. PMID: 35878454 Free PMC article.
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
Visser WCH, de Jong H, Steyaert S, Melchers WJG, Mulders PFA, Schalken JA. Visser WCH, et al. Among authors: mulders pfa. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):583-589. doi: 10.1038/s41391-022-00562-1. Epub 2022 Jul 9. Prostate Cancer Prostatic Dis. 2022. PMID: 35810263 Free PMC article.
Kidney tumor diffusion-weighted magnetic resonance imaging derived ADC histogram parameters combined with patient characteristics and tumor volume to discriminate oncocytoma from renal cell carcinoma.
van Oostenbrugge TJ, Spenkelink IM, Bokacheva L, Rusinek H, van Amerongen MJ, Langenhuijsen JF, Mulders PFA, Fütterer JJ. van Oostenbrugge TJ, et al. Among authors: mulders pfa. Eur J Radiol. 2021 Dec;145:110013. doi: 10.1016/j.ejrad.2021.110013. Epub 2021 Oct 30. Eur J Radiol. 2021. PMID: 34768055 Free article.
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA, Klaver OS, Sedelaar JPM, Van Criekinge W, de Jong H, Mulders PFA, Crawford ED, Veltman J, Schalken JA, Barentsz JO, van Oort IM. Hendriks RJ, et al. Among authors: mulders pfa. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1110-1119. doi: 10.1038/s41391-021-00367-8. Epub 2021 May 3. Prostate Cancer Prostatic Dis. 2021. PMID: 33941866 Free PMC article.
Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma.
Merkx RIJ, Lobeek D, Konijnenberg M, Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA, Rijpkema M. Merkx RIJ, et al. Among authors: mulders pfa. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3277-3285. doi: 10.1007/s00259-021-05271-w. Epub 2021 Mar 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 33651116 Free PMC article. Clinical Trial.
123 results